Cytokine producing ability of peripheral blood cells from COVID-19 patients after unspecific in vitro stimulation.
Adult
Aged
Anti-Inflammatory Agents
/ therapeutic use
Blood Cells
/ drug effects
COVID-19
/ blood
Cells, Cultured
Cytokines
/ blood
Female
Glucocorticoids
/ therapeutic use
Humans
Male
Methylprednisolone
/ therapeutic use
Middle Aged
Mitogens
/ pharmacology
Phytohemagglutinins
/ pharmacology
SARS-CoV-2
COVID-19 Drug Treatment
COVID-19
Cytokine
Glucocorticosteroid
In vitro
Inflammation
Phytohemagglutinin
Journal
Inflammation research : official journal of the European Histamine Research Society ... [et al.]
ISSN: 1420-908X
Titre abrégé: Inflamm Res
Pays: Switzerland
ID NLM: 9508160
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
24
10
2021
accepted:
29
01
2022
revised:
29
12
2021
pubmed:
15
2
2022
medline:
18
3
2022
entrez:
14
2
2022
Statut:
ppublish
Résumé
Perturbations of peripheral T cell homeostasis and dysregulation of the immune response to SARS-CoV-2, especially in severely ill patients, were observed. The aim of this study was to analyze the cytokine producing ability of peripheral blood cells from severely ill COVID-19 patients upon non-specific in vitro stimulation with phytohemagglutinin (PHA). Possible associations of cytokine levels with patients' age and gender, glucocorticosteroid therapy, as well as the trend of the inflammatory process at the time of sampling (increased or decreased) were also analyzed. The study included 23 COVID-19 patients and 17 healthy control subjects. The concentrations of selected Th1/Th2/Th9/Th17/Th22 cytokines were determined using a multi-analyte flow assay kit. Our results showed that peripheral blood cells from severely ill COVID-19 patients had a much reduced ability to produce cytokines in comparison to healthy controls. When inflammation was raised, blood cells produced more IL-6 and IL-17, which led to increases of some Th17/Th1 and Th17/Th2 ratios, skewing towards the Th17 type of response. The methylprednisolone used in the treatment of patients with COVID-19 influences the production of several cytokines in dose dependent manner. Our results indicate that the stage of the inflammatory process at the time of sampling and the dose of the applied glucocorticosteroid therapy might influence cytokine producing ability upon non-specific stimulation of T cells in vitro.
Identifiants
pubmed: 35157090
doi: 10.1007/s00011-022-01543-9
pii: 10.1007/s00011-022-01543-9
pmc: PMC8853300
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Cytokines
0
Glucocorticoids
0
Mitogens
0
Phytohemagglutinins
0
Methylprednisolone
X4W7ZR7023
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
331-341Subventions
Organisme : Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja
ID : III41010
Organisme : Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja
ID : ON175069
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Front Immunol. 2021 Sep 01;12:700921
pubmed: 34539631
Viruses. 2020 Feb 25;12(3):
pubmed: 32106567
Int Immunopharmacol. 2021 Jan;90:107225
pubmed: 33302033
J Allergy Clin Immunol. 2012 Jun;129(6):1438-49; quiz1450-1
pubmed: 22657405
Front Med (Lausanne). 2021 Jan 27;7:603961
pubmed: 33585507
PLoS One. 2021 Jun 29;16(6):e0253894
pubmed: 34185801
J Allergy Clin Immunol. 2020 Sep;146(3):518-534.e1
pubmed: 32896310
Crit Care. 2019 Mar 27;23(1):99
pubmed: 30917856
Int J Biol Sci. 2020 Jul 9;16(14):2479-2489
pubmed: 32792851
J Intensive Care. 2021 Oct 18;9(1):64
pubmed: 34663481
Adv Rheumatol. 2020 Sep 22;60(1):50
pubmed: 32962761
J Immunol. 2005 Aug 15;175(4):2570-8
pubmed: 16081831
Crit Care Explor. 2020 Jun 22;2(6):e0144
pubmed: 32696007
J Endotoxin Res. 2001;7(2):85-93
pubmed: 11521088
Cancer Immunol Immunother. 2015 Jan;64(1):75-82
pubmed: 25297452
Viruses. 2021 Oct 22;13(11):
pubmed: 34834939
Clin Chim Acta. 2020 Oct;509:280-287
pubmed: 32531256
EXCLI J. 2021 Feb 15;20:339-365
pubmed: 33746666
PLoS One. 2020 Dec 31;15(12):e0241097
pubmed: 33382687
Crit Care. 2014 Aug 14;18(4):486
pubmed: 25184344
J Immunol. 1988 Dec 1;141(11):3868-74
pubmed: 3263438
Cell Mol Immunol. 2020 Oct;17(10):1092-1094
pubmed: 32917983
Front Physiol. 2021 Jan 12;11:571416
pubmed: 33510644
J Leukoc Biol. 2020 Jul;108(1):17-41
pubmed: 32534467
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Ann N Y Acad Sci. 2004 Jun;1024:138-46
pubmed: 15265778
Shock. 2000 Mar;13(3):169-74
pubmed: 10718372
Nat Commun. 2020 Jul 6;11(1):3434
pubmed: 32632085
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
Heliyon. 2020 Dec;6(12):e05635
pubmed: 33283062
Signal Transduct Target Ther. 2020 Sep 14;5(1):198
pubmed: 32929061
Cancer Immunol Immunother. 2015 Aug;64(8):1011-9
pubmed: 25971541
Am J Respir Crit Care Med. 2001 Feb;163(2):316-21
pubmed: 11179099
Diabetes Metab Syndr. 2020 Jul - Aug;14(4):407-412
pubmed: 32335367
J Infect. 2020 Jun;80(6):607-613
pubmed: 32283152
Allergy. 2021 Sep;76(9):2866-2881
pubmed: 33884644
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Am J Respir Crit Care Med. 2003 Feb 15;167(4):512-20
pubmed: 12426230
Front Immunol. 2020 May 01;11:827
pubmed: 32425950
JCI Insight. 2020 Sep 3;5(17):
pubmed: 32687484
Front Immunol. 2020 Aug 07;11:1949
pubmed: 32849654
Life Sci. 2021 Feb 15;267:118923
pubmed: 33358906
Cytokine Growth Factor Rev. 2020 Aug;54:62-75
pubmed: 32513566
Clin Immunol. 2000 Jul;96(1):52-66
pubmed: 10873428
Int Immunopharmacol. 2021 Apr;93:107364
pubmed: 33486333
Science. 2020 Aug 7;369(6504):718-724
pubmed: 32661059
Clin Immunol. 2020 May;214:108393
pubmed: 32222466
J Inflamm Res. 2020 Oct 20;13:737-747
pubmed: 33116752